Chlorambucil — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.1-0.2 mg/kg	q24h or q48h	Duration: Continuous or as maintenance; often used for 2-4 weeks initially, then adjusted based on response and blood counts. Notes: For CLL, often used at 0.1-0.2 mg/kg/day. For immune-mediated disease, lower doses (0.1 mg/kg q48h) may be used. Monitor CBC regularly.
Cat	PO	0.1-0.2 mg/kg	q24h or q48h	Duration: Continuous or as maintenance; often used for 2-4 weeks initially, then adjusted. Notes: For low-grade lymphoma, 0.1-0.2 mg/kg/day is common. For immune-mediated disease, 0.1 mg/kg q48h may be used. Monitor CBC.
Horse	PO	0.1-0.2 mg/kg	q24h or q48h	Duration: Limited data; use with caution. Notes: Not commonly used; only under specialist guidance.
Rabbit	PO	0.1-0.2 mg/kg	q24h or q48h	Duration: Limited data; use with caution. Notes: Not commonly used; only under specialist guidance.

Clinical Indications & Species Uses

General Indications

Antineoplastic agent for various lymphoproliferative disorders
Immunosuppressive agent for immune-mediated diseases

Dog (Canine)

Chronic lymphocytic leukemia (CLL)
Lymphoma (as a maintenance or rescue agent)
Multiple myeloma
Immune-mediated diseases (e.g., immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, inflammatory bowel disease, pemphigus)
Macroglobulinemia

Cat (Feline)

Chronic lymphocytic leukemia (CLL)
Lymphoma (especially low-grade alimentary lymphoma)
Immune-mediated diseases (e.g., inflammatory bowel disease, eosinophilic granuloma complex)
Multiple myeloma

Pharmacology & Mechanism of Action

Drug Class: Alkylating agent | Pharmacological Group: Nitrogen mustard derivative

Mechanism of Action: Chlorambucil is a bifunctional alkylating agent that interferes with DNA replication and transcription by forming covalent cross-links between DNA strands, primarily at guanine residues. This leads to DNA fragmentation, inhibition of mitosis, and induction of apoptosis in rapidly dividing cells. It is cell-cycle nonspecific but most active in the S phase.

Pharmacodynamics: Chlorambucil exerts cytotoxic effects on both resting and dividing cells, with a preferential effect on lymphoid tissues. It suppresses humoral and cell-mediated immunity, leading to decreased production of antibodies and T-cell responses. In veterinary medicine, it is used for its immunosuppressive and antineoplastic properties, particularly in chronic lymphocytic leukemia, lymphoma, and immune-mediated diseases.

⚡ Pharmacokinetics Summary

Absorption: Chlorambucil is well absorbed after oral administration, with peak plasma concentrations occurring within 1-2 hours. Bioavailability is high, though food may slightly reduce the rate of absorption.

Distribution: It is extensively bound to plasma proteins (approximately 99%). It distributes widely into body tissues and fluids, including cerebrospinal fluid, though concentrations are lower than in plasma.

Metabolism: Chlorambucil is rapidly metabolized in the liver to its active metabolite, phenylacetic acid mustard, which also has alkylating activity. The parent drug has a short half-life, but the metabolite contributes to prolonged effects.

Excretion: Metabolites are primarily excreted in the urine, with a small fraction eliminated in feces. Renal excretion is the main route of elimination for metabolites.

Half-Life: Dogs: approximately 1.5 hours (parent drug); metabolite half-life ~2.5 hours. Cats: similar or slightly longer. Humans: 1.5-2 hours.

Bioavailability: Oral bioavailability is high, estimated at 70-100% in dogs and cats.

Protein Binding: Approximately 99% bound to plasma proteins.

Available Formulations & Strengths

Oral Tablet 2 mg, 5 mg (PO)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to chlorambucil or other nitrogen mustards
Severe bone marrow suppression (neutropenia, thrombocytopenia)
Pregnancy (teratogenic)
Lactation (may be excreted in milk)
Concurrent administration of live vaccines

Warnings & Clinical Precautions:

Myelosuppression is dose-dependent and may be delayed; monitor complete blood count (CBC) regularly.
Use with caution in patients with hepatic or renal impairment.
May be carcinogenic in the long term; use lowest effective dose.
Handle with gloves; avoid skin contact.
In food animals, extra-label use is prohibited due to lack of withdrawal times.
May cause gastrointestinal upset; administer with food if vomiting occurs.

Adverse Effects & Reactions

Common:

Myelosuppression (neutropenia, thrombocytopenia, anemia)
Gastrointestinal signs (vomiting, diarrhea, anorexia)
Lethargy

Serious / Severe:

Severe bone marrow suppression leading to infection or bleeding
Secondary malignancies (long-term use)
Pulmonary fibrosis (rare)
Seizures (at high doses)

Rare:

Hepatotoxicity
Nephrotoxicity
Skin reactions (rash, urticaria)
Alopecia

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Other immunosuppressive agents (e.g., corticosteroids, cyclosporine, azathioprine)	Additive immunosuppression and increased risk of infection.	Moderate
Myelosuppressive drugs (e.g., other chemotherapeutics)	Increased bone marrow suppression.	High
Live vaccines	Reduced efficacy and increased risk of vaccine-induced disease.	High
NSAIDs	Potential increased risk of gastrointestinal ulceration.	Mild

Overdose & Toxicity Management

Signs of Toxicity:

Severe myelosuppression (pancytopenia)
Gastrointestinal signs (vomiting, diarrhea)
Neurotoxicity (seizures, ataxia)
Hepatotoxicity

Emergency Treatment Protocol: There is no specific antidote. Treatment is supportive: induce vomiting if recent ingestion, administer activated charcoal, provide IV fluids, monitor CBC and organ function, and consider granulocyte colony-stimulating factor (G-CSF) for severe neutropenia. In severe cases, hospitalization and blood transfusions may be necessary.

Food Animal Withdrawal Times

Chlorambucil is not approved for use in food animals. Extra-label use is prohibited due to lack of withdrawal time data and potential carcinogenicity. Do not use in animals intended for food production.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C or 68-77°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in a tightly closed container. Store away from heat.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use.

Extra-Label (Off-Label) Use: In the US, chlorambucil is not FDA-approved for veterinary use, but it can be prescribed legally under the Animal Medicinal Drug Use Clarification Act (AMDUCA) for non-food animals. Extra-label use in food animals is prohibited.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Chlorambucil is a valuable oral alkylating agent used in veterinary oncology and immunotherapy. It is particularly useful for chronic lymphocytic leukemia and low-grade lymphoma in dogs and cats, and as a steroid-sparing immunosuppressant for immune-mediated diseases. Due to its delayed myelosuppressive effects, CBC monitoring is essential, especially during the first few weeks of therapy. Doses should be adjusted based on hematologic parameters. It is generally well tolerated, but gastrointestinal upset can occur; administering with food may help. Long-term use carries a risk of secondary malignancies, so it should be used at the lowest effective dose for the shortest duration possible. In cats, it is often used in combination with prednisolone for alimentary lymphoma. Always handle with care due to its carcinogenic potential.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)